Aripiprazole: A novel antipsychotic with dopamine stabilizing properties

Professional Psychology: Research and Practice

Volumn 34, Issue 1, 2003, Pages 108-111

  Rivas Vazquez, Rafael A ^a  

^a MIAMI RESEARCH ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0037263402     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7028.34.1.108     Document Type: Review

References (23)

1. Baldessarini, R. J., & Tarazi, F. I. (1996). Brain dopamine receptors: A primer on their current status. Harvard Review of Psychiatry, 3, 301-325.
2. 2 receptors. Journal of Pharmacology & Experimental Therapeutics, 302, 381-389.
3. De Keyser, J. (1993). Subtypes and localization of dopamine receptors in human brain. Neurochemistry International, 22, 83-93.
4. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry, 49, 538-544.
5. Frei, R. (2002). Novel agent demonstrates efficacy for schizophrenia. CNS News, 4(9), 6.
6. 2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Molecular Brain Research, 55, 285-292.
7. 2A receptor, European Journal of Pharmacology, 441, 137-140.
8. Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & All, M. W. (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry, 63, 763-771.
9. 2 receptor. Implications for atypical antipsychotic action. Journal of Psychiatry & Neuroscience, 25, 161-166.
10. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis. American Journal of Psychiatry, 158, 360-369.
11. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157, 514-520.
12. 2 receptor antagonistic activity. Journal of Pharmacology & Experimental Therapeutics, 274, 329-336.
13. McGavin, J. K., & Goa, K. L. (2002). Aripiprazole. CNS Drugs, 16, 779-786.
14. Meltzer, H. Y. (1996). Preclinical pharmacology of atypical antipsychotic drugs: A selective review. British Journal of Psychiatry, 168(Suppl. 29), 23-31.
15. 2 pKi values. Journal of Pharmacology & Experimental Therapeutics, 251, 238-246.
16. Ozdemir, V., Fourie, J., & Ozdener, F. (2002). Aripiprazole. Current Opinion in Investigational Drugs, 3, 113-120.
17. Poole, R. (2002). Aripiprazole shows advantages over established antipsychotics. Inpharma Weekly, 1343, 9-11.
18. See, R. E., & Ellison, G. (1990). Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats. Psychopharmacology, 100, 404-412.
19. Stahl, S. M. (2000). Essential pharmacology (2nd ed.). New York: Cambridge University Press.
20. Stahl, S. M. (2001). Mechanism of action of atypical antipsychotics: "Hit-and run" actions at dopamine receptors (Part 1). Journal of Clinical Psychiatry, 62, 670-671.
21. Sugiyama, A., Satoh, Y., & Hashimoto, K. (2001). In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicology & Applied Pharmacology, 173, 120-128.
22. Tamminga, C. A. (2002). Partial dopamine agonists in the treatment of psychosis. Journal of Neural Transmission, 109, 411-420.
23. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography. Neuropsychopharmacology, 27, 248-259.